US 11753466
Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof
granted A61KA61K2039/505A61K31/537
Quick answer
US patent 11753466 (Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof) held by CytomX Therapeutics, Inc. expires Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CytomX Therapeutics, Inc.
- Grant date
- Tue Sep 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 64
- CPC classes
- A61K, A61K2039/505, A61K31/537, A61K47/68033, A61K47/6849